The Three Faces of POTS: A Clinical Map of Hyperadrenergic, Neuropathic, and Hypovolemic Subtypes

Postural orthostatic tachycardia syndrome is treated, in most clinics, as a single condition. The clinical reality is that POTS is at least three distinct physiologies wearing the same diagnostic label. A patient who is hyperadrenergic does not respond to the same protocol as a patient who is hypovolemic. The most common reason POTS treatment fails is that the underlying subtype was never identified. Subtype-aware care is one of the most underused tools in dysautonomia medicine.

The Shared Definition

POTS is diagnosed by a sustained heart rate rise of 30 bpm or more within 10 minutes of standing (40 bpm in adolescents), in the absence of orthostatic hypotension, accompanied by symptoms of orthostatic intolerance (StatPearls — POTS). Underneath that single criterion sit at least three different mechanisms, often overlapping in the same patient (Standing Up to POTS).

Subtype 1: Hyperadrenergic POTS

The Mechanism

Excessive sympathetic nervous system activation. The body releases too much norepinephrine on standing — and often at baseline. The heart rate surges not from peripheral compensation but from direct catecholamine drive.

The Clinical Signature

• Standing plasma norepinephrine ≥ 600 pg/mL — the diagnostic hallmark
• Rise in systolic blood pressure of 10 mmHg or more on standing (distinct from other subtypes, in which BP tends to fall or stay flat)
• Tremor, anxiety, flushing, headache, and feeling "wired and tired"
• Symptoms worse with stress, heat, exertion

A 2024 Vanderbilt study reported mean standing norepinephrine of 744 pg/mL in hyperadrenergic patients versus 415 pg/mL in non-hyperadrenergic POTS — a clear biochemical separation (CognitiveFX summary).

Treatment Implications

• Beta-blockade often helpful — particularly low-dose propranolol
• Central sympatholytics like clonidine or guanfacine may be appropriate
• Standard "drink more salt water" protocols help less than in other subtypes
• Vagal restoration is essential — these patients are sympathetically dominant by definition

Subtype 2: Neuropathic POTS

The Mechanism

Impaired peripheral vasoconstriction, typically from small fiber neuropathy. Blood pools in the legs and abdomen on standing because the vessels fail to clamp down. The heart races to compensate.

The Clinical Signature

• Blood pressure that drops or stays flat on standing (unlike hyperadrenergic POTS)
• Visible blood pooling — dependent acrocyanosis (purple feet on standing)
• Often a history of viral illness (including SARS-CoV-2), autoimmune disease, or diabetes
• Frequent overlap with small fiber neuropathy findings — burning, tingling, hypersensitivity

Skin punch biopsy with intraepidermal nerve fiber density quantification is the gold standard for confirming the small fiber neuropathy component (Neurology, 2024).

Treatment Implications

• Compression garments — particularly abdominal and thigh-high
• Salt and volume expansion are foundational
• Midodrine often more effective here than in hyperadrenergic POTS
• Address the underlying SFN cause where identifiable (autoimmune, metabolic, post-infectious)

Subtype 3: Hypovolemic POTS

The Mechanism

Reduced plasma blood volume, often driven by dysfunction of the renin-angiotensin-aldosterone system. The cardiovascular system has less fluid to work with; standing produces tachycardia by simple hemodynamic necessity.

The Clinical Signature

• 24-hour urine sodium under 100 mmol/L (suggests inadequate salt retention)
• Low aldosterone or paradoxically low renin in some patients
• Profound thirst, salt cravings, dry skin
• Often the most responsive subtype to aggressive hydration and salt loading

Treatment Implications

• Fluid loading — 2.5 to 3 L water daily
• Sodium intake — 8–10 g daily, with electrolyte balance
• Fludrocortisone in selected patients
• IV saline as a rescue intervention in flare states

The Critical Caveat: These Are Not Mutually Exclusive

Many patients meet criteria for more than one subtype. A hyperadrenergic POTS patient with small fiber neuropathy is common. A hypovolemic POTS patient with secondary hyperadrenergic activation from chronic under-volume is common. Subtype assignment is a starting point for treatment design — not a permanent label.

The Shared Vagal Foundation

Across all three subtypes, restoring vagal tone is foundational. Every POTS patient has some degree of autonomic dysregulation, and the parasympathetic side of the equation is consistently impaired. Specific subtype protocols sit on top of a shared vagal-restoration base:

• Daily six-per-minute breathing
• Cold-water face immersion
• Recumbent reconditioning before upright training (8+ weeks)
• HRV biofeedback for progress tracking
• Sleep prioritization
• Address comorbidities — hEDS, MCAS, mast cell instability — which are common